Every headline mentioning Biogen from Nasdaq and BioPharma Dive over the last 30 days, each scored for sentiment and importance. Updated automatically through the trading day.
Fintel reports that on October 29, 2026, Argus Research upgraded their outlook for Biogen (NASDAQGS:BIIB) (WBAG:BIIB) from Hold to Buy.Biogen Inc., based in the United States, is a prominent biotechnology firm operating in the…
Biogen Inc. reported its financial results for the third quarter ended September 30, 2026, with total revenue of $2.8 billion, representing an 11% increase year-over-year. The company's Growth Portfolio revenue reached $1.26 billion, an…
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."